Data Sheet

HMO Series

Recombinant Yeast Fermentation | ≥98% Target Purity

Quality Summary

By utilizing a robust yeast platform, our HMO production eliminates the risk of endotoxin impurities associated with legacy E.coli methods. This ensures a cleaner baseline for downstream formulation. We are capable of supplying stable, multi-ton batches to global formula manufacturers.

Available Specifications

2'-FL (2'-Fucosyllactose)

Standardized high-purity powder

LNnT (Lacto-N-neotetraose)

High uniformity

LNT (Lacto-N-tetraose)

Stringent microbial limits

3-FL (3-Fucosyllactose)

Batch documentation and technical review support available

Contact Sales

Send specs and volume estimates—our team will reply with next steps and technical coordination.

Contact Sales
HMO Series | Morika Bio